Chimeric Therapeutics Limited (CHMMF)

Chimeric Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is July - June.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 5, 2024	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021
Market Capitalization	6	5	12	13	27	72
Market Cap Growth	7.95%	-54.79%	-8.78%	-52.46%	-62.53%	-
Enterprise Value	2	2	9	10	18	76
Last Close Price	0.00	0.00	0.03	0.01	-	-
PS Ratio	0.75	0.64	2.35	4.27	14.95	-
PB Ratio	4.84	4.08	7.09	3.40	1.52	3.82
P/TBV Ratio	-	-	-	-	3.25	8.49
EV/Sales Ratio	0.24	0.24	1.88	3.47	9.82	-
Net Debt / Equity Ratio	-2.92	-2.92	-1.24	-0.42	-0.71	-0.89
Net Debt / EBITDA Ratio	1.06	1.06	0.27	0.10	1.35	1.60
Net Debt / FCF Ratio	0.79	0.79	0.41	0.14	1.40	2.53
Asset Turnover	0.69	0.69	0.40	0.16	0.07	-
Quick Ratio	0.71	0.71	0.31	0.61	2.33	3.05
Current Ratio	0.72	0.72	0.32	0.64	2.35	3.08
Return on Equity (ROE)	-469.35%	-469.35%	-308.21%	-165.25%	-62.55%	-120.59%
Return on Assets (ROA)	-22.01%	-22.01%	-40.86%	-54.54%	-25.52%	-50.84%
Return on Capital Employed (ROCE)	-93.20%	-93.20%	-237.70%	-325.20%	-56.40%	-50.90%
Earnings Yield	-109.09%	-129.40%	-71.52%	-134.60%	-40.63%	-15.75%
FCF Yield	-	-90.26%	-43.02%	-84.69%	-33.65%	-9.22%
Buyback Yield / Dilution	-94.34%	-94.34%	-60.57%	-20.37%	-97.88%	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.